Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
M Lim, M Weller, A Idbaih, J Steinbach… - Neuro …, 2022 - academic.oup.com
Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …
Impact of temozolomide on immune response during malignant glioma chemotherapy
S Sengupta, J Marrinan, C Frishman… - Journal of Immunology …, 2012 - Wiley Online Library
Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a
median survival time of 15 months. The established therapeutic regimen includes a tripartite …
median survival time of 15 months. The established therapeutic regimen includes a tripartite …
Considering the experimental use of temozolomide in glioblastoma research
VJ Herbener, T Burster, A Goreth, M Pruss… - Biomedicines, 2020 - mdpi.com
Temozolomide (TMZ) currently remains the only chemotherapeutic component in the
approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour …
approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour …
DFT investigation on the application of pure and doped X12N12 (X = B and Al) fullerene-like nano-cages toward the adsorption of temozolomide
BL Ndjopme Wandji… - Royal Society …, 2022 - royalsocietypublishing.org
The sensitivity of pure and doped X12N12 (X= B and Al) fullerene-like nano-cages (FLNs)
toward the anti-cancer drug temozolomide (TMZ) is probed herein at DFT/M06-2X-D3/6 …
toward the anti-cancer drug temozolomide (TMZ) is probed herein at DFT/M06-2X-D3/6 …
[HTML][HTML] Cytotoxic activity and Magnetic Behavior of green synthesized iron oxide nanoparticles on brain glioblastoma cells
Iron oxide nanoparticles are one of the most applied metal nanoparticles with advantageous
properties in biomedicine that can be cost-effectively and rapidly produced through green …
properties in biomedicine that can be cost-effectively and rapidly produced through green …
Temozolomide and other potential agents for the treatment of glioblastoma multiforme
This article provides historical and recent perspectives related to the use of temozolomide
for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the …
for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the …
A nanoantidote alleviates glioblastoma chemotoxicity without efficacy compromise
Cancer patients suffer from the toxicity of chemotherapy. Antidote, given as a remedy limiting
poison, is an effective way to counteract toxicity. However, few antidotes abrogate …
poison, is an effective way to counteract toxicity. However, few antidotes abrogate …
Interleukin‐13 receptor alpha 2‐targeted glioblastoma immunotherapy
S Sengupta, B Thaci, AC Crawford… - BioMed Research …, 2014 - Wiley Online Library
Glioblastoma (GBM) is the most lethal primary brain tumor, and despite several refinements
in its multimodal management, generally has very poor prognosis. Targeted immunotherapy …
in its multimodal management, generally has very poor prognosis. Targeted immunotherapy …
Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis
B Neumann, J Onken, N König, H Stetefeld… - Journal of Neuro …, 2023 - Springer
Purpose Patients with glioblastoma are exposed to severe symptoms and organs failures
(eg, coma or acute respiratory failure), that may require intensive care unit (ICU) admission …
(eg, coma or acute respiratory failure), that may require intensive care unit (ICU) admission …
The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes
Glioblastoma is both the most common and most lethal primary CNS malignancy in adults,
accounting for 45.6% of all malignant CNS tumors, with a 5-year survival rate of only 5.0 …
accounting for 45.6% of all malignant CNS tumors, with a 5-year survival rate of only 5.0 …